title: [Spironolactone in dermatological treatment. On and off label indications].
abstract: There are no currently FDA/EMEA-approved dermatologic indications for spironolactone and its off-label uses are, among others, female acne, female pattern hair loss, hidradenitis suppurativa or hirsutism. The rationale behind these relays on the mechanism of action of spironolactone which interferes with the hormone-controlled sebum and sweat gland secretion and with androgen stimulated hair growth. The average dose used by the dermatologits is 50-100 mg daily. It should not be used in pregnant and lactating women and it is not used in men due to the risk of feminization. Although further studies to assess its efficacy and safety are necessary, currently spironolactone is regarded as a useful tool in the dermatologic treatment armamentarium.
authors.affiliation: 2nd Clinic of Dermatology, "Colentina" Clinical Hospital, Bucharest, Romania, galati1968@yahoo.com.
authors.forename: C M
authors.initials: CM
authors.lastname: Salavastru
authors.forename: K
authors.initials: K
authors.lastname: Fritz
authors.forename: G S
authors.initials: GS
authors.lastname: Tiplica
mesh_terms: D002908:Chronic Disease; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology* / Q000517:prevention & control; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D056687:Off-Label Use; D012871:Skin Diseases / Q000188:drug therapy*; D013148:Spironolactone / Q000008:administration & dosage* / Q000009:adverse effects*; D016896:Treatment Outcome; D016387:Women's Health
chemical_list: D003879:Dermatologic Agents; D013148:Spironolactone